Oing, Christoph

Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis

Messina, C., Giunta, E. F., Signori, A., Rebuzzi, S. E., Banna, G. L., Maniam, A., Buti, S., Cattrini, C., Fornarini, G., Bauckneht, M., et al. (2024) · European Urology Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 39

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

Gillessen, S., Murphy, L., James, N. D., Sachdeva, A., El-Taji, O., Abdel-Aty, H., Adler, A. I., Amos, C., Attard, G., Varughese, M., et al. (2025) · The Lancet Oncology

Metabolism, Diabetes, and CancerProstate Cancer Treatment and Research

Cited by 28